Category Archives: MS Treatment

A High Court judge has said there had been "developments" in the condition of a seven-year-old boy at the centre of a legal dispute over cancer treatment. Mr Justice Bodey had been due to make a ruling on whether Neon Roberts should undergo radiotherapy treatment, following surgery on a brain tumour, against the wishes of his mother Sally. But he told a hearing in the Family Division of the High Court in London that he was not delivering the ruling because of the developments. Ms Roberts, 37, a New Zealander who lives in Brighton, East Sussex, said after the hearing that she could not give more details. Neon's father Ben, who lives in London and is separated from Ms Roberts, said he could not comment. Mr Justice Bodey said Neon's case was being kept under review and a further hearing had been scheduled for December 18. The judge heard argument on Friday about whether doctors should start radiotherapy treatment. Ms Roberts said she feared radiotherapy would cause Neon long-term harm. But doctors said Neon might die within months without the treatment. Mr Roberts had agreed to radiotherapy but was "apprehensive", the court heard. The judge said Neon's illness was the … Continue reading →

A High Court judge is to decide whether a seven-year-old boy can undergo radiotherapy treatment following surgery on a brain tumour. On Friday, Mr Justice Bodey heard that Neon Roberts' mother Sally did not want doctors to begin radiotherapy treatment. Ms Roberts, 37, of Brighton, East Sussex, told a High Court hearing in London she feared that radiotherapy would cause Neon long-term harm. But doctors said Neon might die within months without radiotherapy treatment and urged the judge to give them the go-ahead. Mr Justice Bodey said he would announce his decision later. He said neither any hospital where Neon received treatment nor any medic involved should be identified in reports. Neon's father Ben, who lives in London and is separated from Ms Roberts, had agreed to radiotherapy but was "apprehensive", the court heard. Mr Justice Bodey said Neon's illness was the "stuff of every parent's nightmare". He said he would balance what radiotherapy treatment would achieve against the "downsides". Read more: Judge to make radiotherapy ruling … Continue reading →

Gloria Rand - SEO Copywriter has launched a new website called LetGoofIBs.com that promotes alternative treatments for digestive disorders like Irritable Bowel Syndrome. Ms. Rand provided SEO copywriting and social media marketing services to LetGoofIBS.com founder, author and coach, Elizabeth Pry. Oviedo, FL (PRWEB) December 05, 2012 Elizabeth Pry hired Gloria Rand to provide SEO copywriting and social media marketing services for her new business. The project involved writing keyword-rich copy and meta tags, enabling LetGoofIBS.com to display on a search engine results page when IBS sufferers type a query into sites like Google and Bing. Gloria has been such a support throughout this process. I had literally no working knowledge about SEO and she seamlessly developed my plan, provided compelling copy and continues to guide me as I become more fluent in the Social Media and SEO world, said Elizabeth Pry. Gloria also recommended the creation of a lead capture device that could be included on the website to collect email addresses. She edited Ms. Prys special report, Mind Over Gut and designed the reports cover art for the website. Gloria wrote a series of autoresponder emails that are sent to each person who requests the special report. And … Continue reading →

HARRINGTON PARK, N.J.--(BUSINESS WIRE)-- United Water announced today that Lisette Provencher, senior vice president, operations support, for United Water, has been elected to serve on the Board of Governors of the World Water Council. Bernard Guirkinger, Senior Executive Vice President of United Waters parent company SUEZ ENVIRONNEMENT was elected as an Alternate Representative for Ms. Provencher. The World Water Council, representing some 350 organizations in more than 70 countries, works to ensure water security. Ms. Provencher is one of 36 governors, drawn from 13 countries and six international and intergovernmental organizations. She was elected by majority vote from among 64 candidates and will serve until 2015, when the World Water Forum, an international triennial gathering, next convenes. Ms. Provencher succeeds Patrick Cairo, senior vice president, corporate development, of United Water, who served on the Board of Governors of the World Water Council for six years. The elections took place in November during the councils general assembly for which 240 participants had gathered in Marseille, France. Having focused during the past three years on increasing awareness, fostering dialogue and encouraging the emergence of solutions, the World Water Council is now moving forward in three strategic directions: water security for human essential … Continue reading →

EXTON, Pa.--(BUSINESS WIRE)-- BioTrends Research Group, one of the worlds leading research and advisory firms for specialized biopharmaceutical issues, finds that Novartiss Gilenya captures 5.4 percent of those multiple sclerosis (MS) patients treated with disease-modifying agents (DMAs) in the EU5 (France, Germany, Italy, Spain, and the U.K.). This represents an increase from 2.3 percent share one year ago, with significant growth seen among relapsing remitting MS (RRMS), primary relapsing MS (PRMS) and secondary progressive MS (SPMS) patient segments. Consistent with this growth in patient share, neurologists rate their overall satisfaction with Gilenya and its performance on efficacy-related attributes, such as relapse rate reduction, long-term, sustained efficacy and clinical data support, significantly higher compared to 2011. However, it is important to highlight that neurologists rate Biogen Idec/lans Tysabri significantly higher on overall satisfaction and performance than all other commercially available DMAs, likely due to positive perceptions of Tysabris performance on efficacy-related attributes. TreatmentTrends: Multiple Sclerosis (EU) 2012 report also finds that the greatest percent of neurologists continue to voice a first-line preference for Biogen Idecs Avonex or a high dose/high frequency interferon (Merck Seronos Rebif for RRMS and Bayers Betaferon for progressive MS). However, compared to 2011, significantly more neurologists report … Continue reading →

Josh Harding, 13-12-0-4 with a 2.62 GAA last season, has also battled hip and knee injuries that required surgery. Hannah Foslien/AP MINNEAPOLIS (AP) -- Josh Harding didn't feel right. The Minnesota Wild goalie became dizzy during a workout on the ice about two months ago, and he started seeing big, black dots. The neck problem he had was much more than that. Doctors diagnosed him with multiple sclerosis after a series of tests, and he's been undergoing treatment since then for the disease, which attacks the body's immune system and affects the central nervous system. Symptoms can include problems with balance, vision and fatigue. But the 28-year-old Harding, who resumed on-ice workouts two weeks ago without trouble, has no plans to end or alter his career. He said his goal is to be ready if the NHL lockout ends soon. "I'm going to do my part over here, skating regularly, working out regularly, getting back into shape and hopefully be good to go for training camp," Harding said after an informal workout on Thursday with some of his Wild teammates and other NHL players at the University of Minnesota. They've been trying to stay sharp at the local rinks while … Continue reading →

Kathy DeMellier appointed as Director of Admissions at The Pinnacle Schools in Huntsville Alabama. Ms. DeMellier will guide families through the selection and admission process of placing their troubled teen in a residential treatment program. Huntsville, Alabama (PRWEB) December 02, 2012 Ms. DeMellier was raised in Columbus, Ohio and later moved to Alabama where she has been residing for the past 26 years. She earned a Bachelors Degree in Social Work from Auburn University and later went on to earn her Masters Degree in Counseling. Since 1993, Kathy has worked with adolescents, their families and professionals in residential settings. She has served in varying roles in the residential programs including clinical, administrative and admissions.Kathy enjoys spending time with her family and friends, raising her daughter, painting and traveling. We are pleased to welcome Kathy and look forward to working with someone with such extensive experience, Ms. Lee said. The Pinnacle School Huntsville offers a blended learning model for instruction using an approved computer-based curriculum, highly qualified teachers in the classroom, and other supplements to allow students a self-paced instructional setting. Additionally, students are offered other services to promote learning and life skills development such as group counseling, anger management, coping … Continue reading →

Minnesota Wild goaltender Josh Harding is about to begin the fight of his life. Michael Russo of the Star Tribune reported Wednesday night that Harding has been diagnosed with multiple sclerosis, an incurable autoimmune disease in which the body randomly attacks and eats away the protective lining of his nerves and causes them to scar. It results in problems with balance, fatigue and blurred vision. Harding received the news approximately a month ago and has begun the process of informing friends and family, including Wild general manager Chuck Fletcher and coach Mike Yeo. Harding told the newspaper he has no plans of retiring. "I had a couple days where I felt bad for myself, but no more," Harding told Russo. "There's things in life that happen. Sometimes you can't explain it. You deal with it." Fletcher said, "Josh's competitive fire has led him to a successful career in the NHL and we know he will approach this new battle in the same manner." Harding began to feel something was wrong in September, when he was experiencing problems with his neck. An MRI exam revealed lesions on his brain, which led to the diagnosis. According to Russo, Harding has been put … Continue reading →

EDINA, MINN.Sitting on a white leather couch in the living room of his suburban Minneapolis home, Josh Harding doesnt get emotional as he tells his story. He looks completely healthy. He doesnt seem scared. He speaks so confidently, so courageously, youd never know his life has been altered forever. I dont look at this like Ive got to take a new path, said Harding, drafted 10 years ago by the Wild and months off signing a new three-year contract. This is a little bump in the road. Ive had lots in life. Harding, 28, has been diagnosed with multiple sclerosis, an incurable autoimmune disease in which the body randomly attacks and eats away the protective lining of his nerves and causes them to scar. It causes problems with balance, fatigue and blurred vision. There are 25,000 new cases diagnosed in the United States every year. I had a couple days where I felt bad for myself, but no more, said Harding, who plans on continuing his career. Theres things in life that happen. Sometimes you cant explain it. You deal with it. After keeping the disease private from everyone other than his immediate family for more than a month, Harding … Continue reading →

BRISTOL, England & HASSELT, Belgium--(BUSINESSWIRE)-- Apitope, the European drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion of recruitment into its second Phase I clinical trial of ATX-MS-1467 in patients with multiple sclerosis (MS). Receipt of the first dose of study treatment by the last patient to be recruited prompted an undisclosed clinical milestone payment from Merck Serono, a division of Merck, Germany, with whom Apitope is developing ATX-MS-1467. ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the entire immune system, and thus restore immunological balance. ATX-MS-1467 has already completed successfully a Phase I clinical trial in six patients with secondary progressive MS (SPMS). Based on these encouraging preliminary results, a second Phase I clinical trial has been implemented to assess the safety of ATX-MS-1467 as well as biological parameters in a group of 40patients with relapsing MS. The clinical trial is being carried out at two hospitals in the UK, as well as 12 clinics in Russia. Dosing of ATX-MS-1467 is expected to be complete by the … Continue reading →